Tuesday, July 28, 2026
← Back to archivePolicy
Policy•Endpoints News•Jul 27, 2026
Six wellness peptides win backing from FDA advisory committee
background ▾
- •FDA advisory committee voted to remove restrictions on six wellness peptides, representing a notable policy shift toward the expanding peptide wellness sector
- •The decision follows extended deliberation (two-day meeting), suggesting substantive regulatory reconsideration rather than routine approval
- •Monitor for formal FDA response and any guidance on peptide classification, marketing claims, and enforcement priorities in the wellness category
Policy•STAT News•Jul 28, 2026
After PCOS became PMOS, there’s hope for new awareness among Black and Latina women
background ▾
- •PCOS rebranded as PMOS to reflect its systemic endocrine and metabolic pathology; Black and Latina women experience 2x higher prevalence and more severe manifestations than white women, with significant diagnostic delays and health disparities
- •Up to 70% of PMOS cases globally remain undiagnosed; no single diagnostic test exists, and historical research gaps in women of color populations complicate recognition and treatment optimization
- •The nomenclature shift may catalyze new therapeutic approaches and increased clinical attention to underserved populations, though implementation and addressing structural healthcare access barriers will require sustained effort
Policy•KFF•Jul 27, 2026
Donor Government Funding for HIV in Low- and Middle-Income Countries in 2025
background ▾
- •U.S. funding cuts drove a $2.1 billion (25%) year-over-year decline in global HIV donor government funding—the largest drop in the 23-year history of the scale-up—dropping to 2007 levels at $6.2 billion
- •The America First Global Health Strategy, USAID restructuring, and project cancellations by the U.S. (the world's largest HIV donor) are the primary drivers, with plans to further scale down U.S. support in coming years
- •Monitor the 2026-2027 funding trajectory and whether other donors increase contributions to offset U.S. reductions; assess impact on HIV treatment access, prevention programs, and disease control in sub-Saharan Africa and other high-burden regions
Policy•KFF•Jul 27, 2026
How Many Uninsured Are in the Coverage Gap and How Many Could be Eligible if All States Adopted the Medicaid Expansion?
background ▾
- •1.2 million uninsured adults in non-expansion states face a coverage gap with incomes too high for state Medicaid but too low for ACA subsidies; this population is predominantly working, people of color, and childless adults
- •The 2025 reconciliation law eliminates ARPA incentives for Medicaid expansion adoption and introduces work requirements starting January 2027 expected to increase uninsured by 5.3 million over ten years
- •Monitor state responses to work requirement implementation and whether any of the ten non-expansion states reconsider expansion given the policy shift, plus CBO tracking of actual coverage losses versus projections
Policy•Endpoints News•Jul 27, 2026
Virginia federal judge says FDA should reconsider mifepristone restrictions
background ▾
- •Federal judge challenges FDA's existing mifepristone restrictions, signaling potential regulatory recalibration
- •Decision comes amid broader federal government reassessment of medication abortion policy, creating regulatory uncertainty for manufacturers
- •Outcome will likely depend on how current FDA administration responds to judicial directive and evolving political/regulatory environment
mifepristone
→ Read original articleMarket Access
Market Access•Fierce Biotech•Jul 27, 2026
RA Capital launches rare disease company Oak Hill Bio onto Nasdaq via SPAC
background ▾
- •Oak Hill secured $175 million in total funding ($75 million from SPAC trust + $100 million from RA Capital) plus prior $32.5 million Series A to fund rugonersen through phase 3 and NDA submission in 2029
- •Rugonersen faces direct competition from at least two other phase 3 programs (Ultragenyx GTX-102 and Ionis ION582) in Angelman syndrome, a rare genetic disorder affecting 1 in 15,000 births
- •Watch for phase 3 BEACON trial progress and regulatory decisions in 2028-2029 as rugonersen competes for first-mover advantage in what could become a crowded Angelman syndrome market
Oak Hill BioRA CapitalResearch Alliance Corporation IIIrugonersenOHB-724GTX-102
→ Read original articleMarket Access•Fierce Biotech•Jul 27, 2026
Apnimed aspires for up to $160M IPO as sleep apnea pill launch nears
background ▾
- •Oxnimbi would be the first non-obesity-restricted prescription drug for OSA if approved, addressing a multi-million patient population currently managed with CPAP devices.
- •Phase 3 efficacy data (46.8% reduction in apneic events across 660 patients) supports regulatory pathway, but approval remains contingent on February FDA decision.
- •IPO timing and capital adequacy hinge entirely on FDA approval; failure or delay would materially impact financing structure and commercial launch velocity.
ApnimedEli LillyPfizerOxnimbiAD109Zepbound
→ Read original articleMarket Access•Fierce Biotech•Jul 27, 2026
FDA approves Freenome colorectal cancer blood test to be marketed by Abbott
background ▾
- •FDA approval of SimpleScreen CRC and Abbott's exclusive U.S. commercialization deal represents a significant market access win in noninvasive colorectal cancer screening, with automatic Medicare coverage expected and American Cancer Society guideline incorporation planned.
- •The test's relatively low sensitivity for advanced precancerous lesions (13.7%) limits it to a secondary screening role per American Cancer Society recommendations, constraining its addressable market to the estimated 60 million unscreened Americans who decline or avoid standard options.
- •Abbott's integration of SimpleScreen with its Nexus digital health platform and existing Cologuard portfolio positions the company to capture a meaningful share of noninvasive screening adoption, but competition from Guardant's Shield test will determine real-world market uptake and payer formulary decisions.
FreenomeAbbottGuardant HealthSimpleScreen CRCShieldCologuard
→ Read original articleMarket Access•Fierce Biotech•Jul 27, 2026
Legend Biotech CEO abruptly steps down without permanent replacement
background ▾
- •Legend Biotech CEO Ying Huang has abruptly resigned after seven years; interim CEO Alan Bash (former president of commercial operations for Carvykti) assumes leadership with no permanent successor identified
- •The leadership change coincides with intensifying competitive threats to Carvykti's market position, particularly from J&J's bispecific antibody regimens (Tecvayli/Darzalex and Tecvayli/Talvey combinations), which have demonstrated superior efficacy in myeloma
- •Watch for permanent CEO appointment timeline and any strategic announcements regarding Legend's pipeline, particularly LB2501, which showed encouraging early data but has failed to sustain investor confidence amid broader competitive and geopolitical concerns
Legend BiotechJohnson & JohnsonGilead SciencesCarvyktiLB2501anito-cel
→ Read original articleMarket Access•Fierce Biotech•Jul 27, 2026
Argenx acquires Forte for $2.2B to get hands on phase 2-stage vitiligo drug
background ▾
- •FB102 is positioned as first-in-class anti-CD122 with best-in-class potential, offering a systemic alternative to topical JAK inhibitors like Opzelura in vitiligo and addressing pathogenic T-cell and NK-cell activity across multiple autoimmune diseases
- •Argenx's $5.2 billion cash position from Vyvgart success provides flexibility to acquire early-stage assets with novel biology, signaling confidence in FB102's mechanism after clinical de-risking in phase 1b
- •Phase 2 celiac disease data expected later in 2024; watch for indication sequencing strategy and subcutaneous formulation development as argenx applies its commercial playbook to expand FB102 into alopecia areata and additional autoimmune conditions
ArgenxForte BiosciencesIncyteFB102Vyvgartempasiprubart
→ Read original articleClinical Trials
Clinical Trials•Fierce Biotech•Jul 27, 2026
After missed endpoint, Gossamer and Chiesi pull the plug on PAH drug collaboration
background ▾
- •Seralutinib missed its primary endpoint (13.3m improvement in 6MWD) by a narrow statistical margin (p=0.032 vs. p=0.025 threshold), yet the FDA pre-NDA meeting indicated this may not block NDA filing.
- •Gossamer regains worldwide rights and a healthier balance sheet after Chiesi's exit, reducing near-term financial pressure and allowing the company to pursue PAH approval independently.
- •Watch for the September NDA submission and FDA's actual response—the critical question is whether regulatory precedent supports approval on secondary endpoints and subgroup analysis when the primary endpoint is missed, especially in the context of competitive PAH therapies from J&J, Merck, and others.
Gossamer BioChiesiJohnson & JohnsonseralutinibUptraviOpsumit
→ Read original articleClinical Trials•Fierce Biotech•Jul 27, 2026
MapLight shares sink on mixed phase 2 schizophrenia readout
background ▾
- •ML-007C-MA achieved primary endpoint with twice-daily dosing but failed with once-daily dosing, representing a partial but incomplete clinical success that triggered severe market punishment despite positive tolerability and cognitive findings
- •Cognitive improvement independent of psychosis symptom reduction could differentiate ML-007C-MA in Alzheimer's disease psychosis, where no approved therapy addresses cognition, potentially offsetting schizophrenia setback
- •Watch for MapLight's further dose optimization analyses and upcoming Alzheimer's disease psychosis phase 2 data, which analysts identify as the program's clearest path to commercial success and potential inflection point for the company
MapLight TherapeuticsBristol Myers SquibbAlphabet/SandboxAQML-007C-MACobenfy
→ Read original articleClinical Trials•Fierce Biotech•Jul 27, 2026
InnoCare’s oral TYK2 inhibitor clears phase 3 psoriasis test
background ▾
- •Fadeucravacitinib met primary and multiple secondary endpoints in phase 3 psoriasis trial, with response rates (77-79% achieving ≥75% PASI improvement) comparable to Sotyktu's phase 2 results but lacking direct comparative data.
- •InnoCare is pursuing regulatory filing in China for a crowded TYK2 inhibitor class where Takeda's zasocitinib has demonstrated superior efficacy to BMS' Sotyktu in head-to-head testing, raising questions about fadeucravacitinib's competitive positioning.
- •Watch for detailed efficacy and safety data publication and InnoCare's regulatory filing timeline; competitive differentiation against zasocitinib and Sotyktu will be critical to market access success in China and potentially beyond.
InnoCare PharmaBristol Myers SquibbTakedafadeucravacitinibICP-488Sotyktu
→ Read original articleClinical Trials•STAT News•Jul 28, 2026
From ‘lost cause’ to gold rush: Biotechs swarm to cure AATD
background ▾
- •AATD represents a rare commercial alignment: a single mutation affecting 200,000 patients treatable by a single therapeutic, making it one of the highest-value opportunities in gene editing today
- •Beam Therapeutics is furthest advanced with a potential 2028 approval filing; at least 11+ companies are pursuing various modalities (gene editing, gene therapy, protein replacement, small molecules), indicating genuine clinical confidence in the opportunity
- •Monitor Beam's clinical data readouts and competitive filing timelines; watch for patent/IP resolutions and China-based competitor emergence; track whether first-mover approval translates to market dominance given multiple pipeline programs
Beam TherapeuticsWave Life SciencesKorro Bio
→ Read original articleClinical Trials•Endpoints News•Jul 27, 2026
AstraZeneca looks to AI to ease risk in late-stage trials, speed up filings
background ▾
- •AstraZeneca is actively developing AI capabilities for late-stage trial risk mitigation and regulatory pathway optimization, though no clinical-stage candidates have yet emerged from these efforts.
- •The company recognizes AI as a competitive differentiator in reducing trial failures and accelerating regulatory submissions, signaling confidence in the technology's potential despite lacking current clinical proof points.
AstraZeneca
→ Read original article